| 臺大學術典藏 |
2022-09-15T01:08:58Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; Chia-Chi Lin; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; Chia-Chi Lin; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. |
| 臺大學術典藏 |
2021-03-09T06:46:02Z |
Pembrolizumab for the treatment of advanced salivary gland carcinoma
|
Cohen R.B.;Delord J.-P.;Doi T.;Piha-Paul S.A.;Liu S.V.;Gilbert J.;Algazi A.P.;Damian S.;Ruey-Long Hong;Le Tourneau C.;Day D.;Varga A.;Elez E.;Wallmark J.;Saraf S.;Thanigaimani P.;Cheng J.;Keam B.; Cohen R.B.; Delord J.-P.; Doi T.; Piha-Paul S.A.; Liu S.V.; Gilbert J.; Algazi A.P.; Damian S.; RUEY-LONG HONG; Le Tourneau C.; Day D.; Varga A.; Elez E.; Wallmark J.; Saraf S.; Thanigaimani P.; Cheng J.; Keam B. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort
|
Seiwert T.Y.; Cheng J.D; Pathiraja K; Dolled-Filhart M; Meister A; Chung H.C; Chow L.Q.M; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder J.P; Burtness B; Lee S.-H; Keam B; Kang H; Muro K; Weiss J; Geva R; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
|
Cheng J; Chow L.Q.M; Haddad R.; Pathiraja K; Aurora-Garg D; Ray A; Chia-Chi Lin; Chung H.C; Geva R; Mehra R; Seiwert T.Y; Gupta S; Weiss J; Gluck I; Eder J.P; Burtness B; Tahara M; Keam B; Kang H; Muro K |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
|
Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1�V4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N; Ryoo B.-Y; Keam B; Kudo M; Chia-Chi Lin; Kunieda F; Ball H.A; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T. |
| 國立成功大學 |
2020 |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai, J.;Deva, S.;Lee, J.S.;Lin, C.-C.;Yen, C.-J.;Chao, Y.;Keam, B.;Jameson, M.;Hou, M.-M.;Kang, Y.-K.;Markman, B.;Lu, C.-H.;Rau, K.-M.;Lee, K.-H.;Horvath, L.;Friedlander, M.;Hill, A.;Sandhu, Sandhu S.;Barlow, P.;Wu, C.-Y.;Zhang, Y.;Liang, Liang L.;Wu, J.;Paton, V.;Millward, Millward M. |
| 國立臺灣大學 |
2015 |
Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
|
Sun, Y.; Shi, H.; Chen, C. -H.; Lee, J. L.; Kang, T. W.; Park, S. H.; Wu, T. L.; Ng, Q. S.; Keam, B.; Wong, S. C. A.; Tay, M. H.; Ding, Q.; Li, F.; Ng, D. C. E.; Liu, X.; Zhang, Z.; Guo, J.; 陳忠信 |
